variable region in operable linkage with at least one human constant region of an anti-human TNFα antibody.

72. The polynucleotide according to Claim 71 wherein said polynucleotide is selected from the group consisting of cDNA and RNA.

73. The polynucleotide according to Claim 72, wherein said polynucleotide is an expression vehicle.

74. The polynucleotide according to Claim 73, wherein said polynucleotide encodes said at least one variable region or said at least one constant region, wherein at least a portion or said polynucleotide hybridizes to at least a 15 base oligonucleotide complimentary to the sequence presented in Figure 17A (SEQ ID NO: 2) or Figure 17B (SEQ ID NO: 3).

75. The polynucleotide according to Claim 73, wherein said antibody binds amino acids 87-108, or both 59-80 and 87-108 of SEQ ID NO: 1 of hTNFα.

76. The polynucleotide according to Claim 73, wherein said antibody does not bind to one or more epitopes included in amino acids 11-13, 37-42, 49-57 or 155-157 of SEQ ID NO: 1 of hTNFα.

77. The polynucleotide according to Claim 73, wherein said antibody comprises two light chains and two heavy chains, each of said chains comprising at least part of a constant region and at least part of a variable region, said variable region capable of biding an epitope specific for human TNFα.

78. The polynucleotide according to Claim 73, wherein said epitope is a neutralizing epitope of human TNFα under physiological conditions.

79. The polynucleotide according to Claim 73, wherein said variable region is of murine origin.

80. The polynucleotide according to Claim 73 which encodes cA2.

81. A host transformed or transfected with a polynucleotide according to Claim 73.

82. The host according to Claim 81, wherein said host is selected from the group consisting of a eukaryotic cell and a bacterial cell.

83. The host according to Claim 82, wherein said host is a eukaryotic cell selected from the group consisting of a yeast cell, an insect cell and a mammalian cell.

84. An isolated polynucleotide which encodes an isolated immunoreceptor molecule, comprising at least part of a human immunoglobulin heavy chain CH_1 or CH_2 region, at least a portion of a immunoglobulin hinge region, and anti-TNF peptide capable of binding an epitope specific for a human TNF.

85. The polynucleotide of Claim 84 wherein the anti-TNF peptide is selected from a TNF receptor fragment, an epitope binding region of an anti-TNF antibody, and a TNF-binding peptide.

86. The polynucleotide of Claim 85 wherein said anti-TNF peptide is a fragment of TNF receptor, p55.

87. The polynucleotide of Claim 85 wherein said anti-TNF peptide is a fragment of TNF receptor, p75.

88. The polynucleotide of Claim 85 wherein the fragment comprises sequences within 2-159 of p55.